Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 5/20 | 0.49 |
| ▸ | ERN1 | O75460 | 3/20 | 0.44 |
| ▸ | F2 | P00734 | 8/20 | 0.43 |
| ▸ | F10 | P00742 | 1/20 | 0.39 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.38 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25035677 | 0.93 | BRAF (0.47) | BRAFERN1F2F10PRSS1 | |
| SCHEMBL25035429 | 0.92 | BRAF (0.48) | BRAFERN1F2F10PRSS1 | |
| SCHEMBL25034178 | 0.89 | BRAF (0.62) | BRAFF2 | |
| SCHEMBL25034174 | 0.88 | ERN1 (0.56) | BRAFERN1F2 | |
| SCHEMBL25034208 | 0.88 | ERN1 (0.55) | BRAFERN1F2F10 | |
| SCHEMBL25035525 | 0.87 | BRAF (0.51) | BRAFF2F10PRSS1 | |
| SCHEMBL25034187 | 0.86 | ERN1 (0.43) | BRAFERN1F2F10PRSS1 | |
| SCHEMBL25035620 | 0.84 | BRAF (0.49) | BRAFF2F10PRSS1 | |
| SCHEMBL25034216 | 0.84 | BRAF (0.53) | BRAFERN1 | |
| SCHEMBL25035330 | 0.84 | ERN1 (0.46) | BRAFERN1F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230047209-A1 | PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AND METHODS OF USE | PARAZA PHARMA, INC. (CA) | 2023-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230047209-A1 | PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AND METHODS OF USE | TYMP, TYMS, DPYD | BRAF 563/4885ERN1 3167/4885F2 1649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.